The HOX Hypothesis: A Novel Approach To Targeted Cancer Therapy
Executive Summary
Emerging Company Profile: With a Phase I clinical trial starting in Q3 and Series A funding to raise, HOX Therapeutics is taking a step out of the shadows of academia to develop its novel drug candidates in brain and prostate cancer. CEO Karl Keegan spoke to Scrip about what is next for the UK company.